A Study of HRS-6208 in Combination With HRS-8080, or Fulvestrant, or Letrozole, With or Without HRS-6209 in Patients With Advanced Unresectable or Metastatic Breast Cancer

This study aims to evaluate the safety, tolerability, efficacy and pharmacokinetics of HRS-6208 in combination with HRS-8080 ± HRS-6209, or in combination with fulvestrant ± HRS-6209, or in combination with letrozole ± HRS-6209 in patients with advanced unresectable or metastatic breast cancer.

Trial Details

NCT ID
NCT07389733
Phase
PHASE1 / PHASE2
Sponsor
Shandong Suncadia Medicine Co., Ltd.
Status
RECRUITING
Cancer Type
Breast Cancer
Interventions
  • HRS-6208 Capsule
  • HRS-6209 Capsule
  • HRS-8080 Tablet
  • Fulvestrant injection
  • Letrozole tablets
Locations (sample)
  • Dalian, Liaoning, China|38.91222,121.60222
  • Chengdu, Sichuan, China|30.66667,104.06667

Key Eligibility Criteria

  • Female, aged 18-75 (inclusive);
  • ECOG score 0-1;
  • Estimated survival time ≥ 12 weeks;
  • Possessing adequate bone marrow and organ function;

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Breast Cancer Trials on Trialify →